University of Geneva (UniGE) – Switzerland
The University of Geneva (UniGe), hosts a 2,200‐bed health care centre (Hôpitaux Universitaires de Genève) providing primary and tertiary care for Geneva, and several experts (Profs Harbarth, Pittet and Schrenzel) who have generated ground‐breaking articles in the field of antibiotic resistance and infection control. This team will guarantee that the proposed clinical study will be coordinated and supervised successfully.The investigators are already co‐ordinating or participating in several international EC‐funded projects (R-Gnosis, Rapp-ID, SATURN,Prohibit, MOSAR,CHAMP, MagRSA).
The Principal Investigator Prof. Stephan Harbarth from UniGe is the lead of WP2 (randomized clinical trial to compare fosfomycin vs. nitrofurantoin for the treatment of lower urinary tract infection in women at high risk of antibiotic‐resistant pathogens) and will coordinate the study.
Previous experience and Key personnel
Prof. Stephan Harbarth (MD, MS) is the scientist in charge of WP 2 of this proposal. He is also coordinator of SATURN and supervises WP3 of SATURN. He is a well‐known infectious disease epidemiologist with extensive research experience in the field of antimicrobial use and resistance. He has deep knowledge in the field of clinical epidemiology and controlled clinical trials. He was recipient of the Young Investigator Awards by the Swiss Society of Infectious Diseases, the European Society of Microbiology and Infectious Diseases and the American Society of Microbiology for research excellence and scientific promise. He is currently hospital epidemiologist, boardcertified attending physician in infectious diseases and senior registrar, with more than 100 original articles in peer‐reviewed journals as 1st, 2nd or last author.
Dr. Angela Huttner (MD) is an infectious disease physician and co-investigator in WP2 of this proposal. Her research in infection control includes (1) strategies to reduce the emergence of antimicrobial resistance through the optimisation of our use and understanding of extant antibiotics, whether old, such as nitrofurantoin and fosfomycin, or relatively new, such as the beta-lactams, and (2) alternative strategies to prevent and control infections, given the dearth of novel antimicrobials in the pipeline today. In this vein she is a co-investigator in controlled trials testing vaccines targeting both resistant bacteria (e.g., E. coli) and viruses (e.g., Ebolavirus). She is currently serving on the Parity Commission of the European Society of Clinical Microbiology and Infectious Diseases as Advocate for Gender.